Genetic variation at CHRNA5-CHRNA3-CHRNB4 interacts with smoking status to influence body mass index.

BACKGROUND: Cigarette smoking is associated with lower body mass index (BMI), and a commonly cited reason for unwillingness to quit smoking is a concern about weight gain. Common variation in the CHRNA5-CHRNA3-CHRNB4 gene region (chromosome 15q25) is robustly associated with smoking quantity in smokers, but its association with BMI is unknown. We hypothesized that genotype would accurately reflect smoking exposure and that, if smoking were causally related to weight, it would be associated with BMI in smokers, but not in never smokers.
METHODS: We stratified nine European study samples by smoking status and, in each stratum, analysed the association between genotype of the 15q25 SNP, rs1051730, and BMI. We meta-analysed the results (n = 24,198) and then tested for a genotype × smoking status interaction.
RESULTS: There was no evidence of association between BMI and genotype in the never smokers {difference per T-allele: 0.05 kg/m(2) [95% confidence interval (95% CI): -0.05 to 0.18]; P = 0.25}. However, in ever smokers, each additional smoking-related T-allele was associated with a 0.23 kg/m(2) (95% CI: 0.13-0.31) lower BMI (P = 8 × 10(-6)). The effect size was larger in current [0.33 kg/m(2) lower BMI per T-allele (95% CI: 0.18-0.48); P = 6 × 10(-5)], than in former smokers [0.16 kg/m(2) (95% CI: 0.03-0.29); P = 0.01]. There was strong evidence of genotype × smoking interaction (P = 0.0001).
CONCLUSIONS: Smoking status modifies the association between the 15q25 variant and BMI, which strengthens evidence that smoking exposure is causally associated with reduced BMI. Smoking cessation initiatives might be more successful if they include support to maintain a healthy BMI.

Introduction

Cigarette smoking is a major preventable cause of death and disease. However, while the majority of smokers report a willingness to quit, only a relatively small proportion attempt to do so in any given year. One reason commonly cited for being unwilling to stop smoking is a concern about weight gain following cessation, and weight gain following smoking cessation has also been associated with an increased risk of smoking relapse.

There is a general consensus that smoking cessation does lead to some degree of weight gain. There is substantial evidence from experimental studies indicating that cigarette smoking exerts an appetite-suppressant effect, and it has long been recognized that cigarette smoking is employed as a means of weight control, particularly by women, possibly mediated via a lowering of the body weight set point following chronic nicotine use. Epidemiological evidence consistently shows that smokers have a lower body mass index (BMI) than non-smokers,, but whether smoking exposure is causal to lower BMI is unclear.

Recently, a number of genome-wide association (GWA) studies have provided robust evidence that genetic variation at the CHRNA5-CHRNA3-CHRNB4 locus on chromosome 15q25 is associated with quantity of smoking in those who smoke. Each additional copy of the T-allele of the single-nucleotide polymorphism (SNP), rs1051730, is associated with an increase in smoking quantity of about one cigarette per day. However, the similarity of allele frequency between ever and never smokers does not support association of this variant with smoking initiation. The rs1051730 SNP lies within the nicotinic acetylcholine receptor-α 3 subunit gene (CHRNA3), but is in linkage disequilibrium with a large number of other SNPs across CHRNA3, CHRNA5 and CHRNB4. The functional variant at the 15q25 locus is not known. The minor allele of the mis-sense polymorphism, D398N (rs16969968), in CHRNA5, conferred a reduced response to a nicotinic agonist in vitro. However, a recent study, which used data from the 1000 Genomes Project to impute virtually all common variants in the region, showed that rs55853698, in the 5′-untranslated region of CHRNA5, was the most strongly associated SNP. Both rs16969968 and rs55853698 are highly correlated with rs1051730 in Europeans (all pairwise r2 > 0.96).

The association between variation at the 15q25 locus and BMI is not known. Since genotypes are (i) assigned at conception and (ii) not generally associated with the wide range of environmental characteristics that confound conventional epidemiological association studies, genetic variation at 15q25 should serve as an unconfounded measure of smoking exposure in smokers, unbiased by reverse causality. If cigarette smoking is causally associated with lower BMI, we would expect the allele that predisposes to heavier smoking to be associated with a lower BMI in those who smoke, but not in those who have never smoked. This would constitute a gene × environment interaction, and would provide strong evidence of causality. To investigate this, we performed a meta-analysis (n = 24 198 participants; k = 9 study samples) to examine the association between the rs1051730 variant and BMI. We stratified our analyses by smoking status, and tested for a genotype × smoking status interaction.

Methods

Study participants

We analysed data on a total of 24 198 participants from nine study samples. All participants gave informed consent and ethical approval was obtained from the relevant local review committees. In each study, BMI was calculated as weight (kg) divided by height squared (m2).

The Avon Longitudinal Study of Parents and Children

This is a prospective study, which recruited pregnant women from Bristol, UK, with expected delivery dates between April 1991 and December 1992. Ethical approval was obtained from the Avon Longitudinal Study of Parents and Children (ALSPAC) Law and Ethics Committee in addition to the local review committee. Data collection on smoking behaviour have been described previously. Women were grouped as never smokers, former smokers or current smokers on the basis of a questionnaire administered in the 18th week of gestation. The latter two categories were combined in analyses that compared strata of never with ever smokers. Pre-pregnancy BMI was calculated from self-reported pre-pregnancy weight and height. We included a total of 6148 women of European ancestry, with rs1051730 genotype, BMI and smoking data available.

The British Regional Heart Study

The study recruited 7735 men aged 40–59 years in 1978–80; full details are reported elsewhere. Men were recruited from 24 medium-sized British towns; at that time, very few eligible subjects were of non-European ancestry. Twenty years later, when aged 60–79 years, n = 4252 participants were re-measured and provided a whole-blood sample from which DNA was extracted. The physical examination included weight and height. Height without shoes and weight in trousers and socks were measured, to the nearest millimetre and 0.1 kg, respectively. Participants were asked whether they had ever smoked cigarettes regularly and, if yes, whether they smoked cigarettes now; from these two questions, we defined current smokers, former smokers and never smokers. Cotinine was assayed by a widely applied gas chromatographic method with a detection limit of 0.1 ng/ml. Regular internal quality controls were run to ensure comparability and reliability of results over time. For non-smokers, cotinine levels were further defined using a liquid chromatography tandem mass spectrometry (LC–MS/MS) assay with a lower limit of detection of 0.02 ng/ml and with a limit of quantification of 0.1 ng/ml. Cotinine values at the limit of quantification (0.1 ng/ml) were assigned a value of 0.05 ng/ml. Further details of the assay can be obtained from abslabs@biopark.org.uk. In the current analyses, we included 3870 participants with rs1051730 genotype, BMI and smoking data available.

The British Women’s Heart and Health Study

The study randomly selected and recruited 4286 women aged 60–79 years, from 23 British towns, between 1999 and 2001. The women were interviewed, examined, completed medical questionnaires and had detailed reviews of their medical records. Full selection and baseline measurement details of the study, including measurement of height and weight (assessed without shoes and in light clothing to the nearest millimetre and 0.1 kg, respectively), have been previously reported., Smoking history (never, former and current, including the amount and details of starting and quitting) were self-reported at baseline, either at the research nurse interview or in the mailed questionnaires. Serum samples collected at baseline were assayed for cotinine levels in exactly the same way as in the British Regional Heart Study (BRHS). After excluding participants of known non-White ethnicity, or who had missing rs1051730 genotype, smoking or BMI data, there were 3634 women available for analysis.

The CoLaus Study

This is a population-based study of 6188 individuals, aged 35–75 years, randomly selected from the list of residents in Lausanne, Switzerland, between 2003 and 2006. Risk factors for cardiovascular diseases were assessed and DNA and plasma samples were collected for the study of genetic variants and biomarkers. Between 2004 and 2008, all 35- to 66-year-old individuals of the CoLaus sample were invited to participate in a psychiatric sub-study (PsyCoLaus). Detailed descriptions of recruitment procedures and assessments have been provided previously., The physical assessment within the CoLaus study included measurement of body weight and height, from which BMI was calculated. Ever smokers were those who had smoked regularly at some point in their life. Of these, individuals who smoked at least one cigarette daily at the time of interview were classified as current smokers, whereas the rest were classified as former smokers. For the purpose of genetic analysis, only individuals with European origin were included (n = 5692), and of these, a total of 5426 participants had the genotype and phenotype data necessary for inclusion in the current study.

The Exeter Family Study of Childhood Health

This is a prospective study of children born between 2000 and 2004, and their parents, from a geographically defined region of Exeter, UK. Data collection on smoking behaviour have been described previously. In the current study, we included 811 pregnant women and 762 men of European ancestry. We grouped them as never, former or current smokers on the basis of questionnaire data collected during the 28th week of gestation. Height and weight were measured at that time by research midwives and used to calculate BMI. Since women were pregnant at the time of data collection, we analysed men and women separately in the current study. For the women-only analysis, we used pre-pregnancy BMI (calculated from self-reported pre-pregnancy weight).

The Danish GOYA Male Study

Among 362 200 Caucasian men examined at the mean age of 20 years at the draft boards in Copenhagen and its surroundings during 1943–77, a randomly selected control group of 1 in every 100 men (n = 3601) and all obese men (n = 1930) were manually identified. Obesity was defined as 35% overweight relative to a local standard in use at the time, and this corresponds to a BMI ≥ 31.0 kg/m2, which proved to be above the 99th percentile. All obese men and half of the random sample, still living in the region, were invited to a follow-up survey in 1992–94 at the mean age of 46 years. The criteria for invitation to the follow-up surveys and the participation have been described previously. A total of 1441 men (661 obese and 780 randomly selected) were included in the present study with BMI, smoking status and rs1051730 genotype data available.

The MIDSPAN Family Study

This is one of the four MIDSPAN population cohort studies based in Scotland. The three original studies took place between 1964 and 1976. Twenty years later, in 1996, the next generation was studied when offspring of couples in the original Renfrew/Paisley Study were recruited into the Family Study. This latter group is the subject of the present analysis. The offspring were ascertained (by self-report) to be from full-sibling families with no step children, adoptees or half-siblings. All were White and living in the west of Scotland. Details of the study have been described previously. Standing height was measured without shoes. A single measurement (to the nearest 1 mm) was made after participants inhaled and stretched to reach their maximum height. Weight was measured to the nearest 0.1 kg without shoes and wearing indoor clothes. Data on smoking habit (never, current or former) were collected via questionnaires completed by the participants. Serum samples were assayed for cotinine at ABS Laboratories Ltd, London, UK. For smokers and non-smokers, capillary column gas–liquid chromatography with a nitrogen detector was used. The lower limit of detection was 0.1 ng/ml. In the current analyses, we included 2106 individuals of European ancestry with rs1051730 genotype, BMI and smoking data available.

Genotyping

The genotyping of the rs1051730 variant in the ALSPAC and The Exeter Family Study of Childhood Health (EFSOCH) studies has been described previously. In the British Women’s Heart and Health Study (BWHHS) and BRHS studies, genotyping of rs1051730 was performed by KBioscience (http://www.kbioscience.co.uk), using KASPar chemistry, which is a competitive allele-specific PCR SNP genotyping system. The respective genotyping call rates were 98.2 and 98.7%, and there was no evidence of deviation from Hardy–Weinberg Equilibrium (HWE; BWHHS P = 0.58; BRHS P = 0.29). In the BWHHS, blind duplicates (concordance 100%) were used as additional quality control tests. In the MIDSPAN study, genotyping was performed on an ABI PRISM 7900HT sequence detection system using a Taqman assay (Assay ID: C_9510307_20, Applied Biosystems), followed by allelic discrimination using software from Applied Biosystems (SDS V2.0)., All genotyping errors were manually resolved by checking raw genotype data, individuals were either blanked (zeroed) or corrected prior to analysis. The call rate was 94.5% and there was no evidence of deviation from HWE (P = 0.92), which was assessed using the eldest sibling from each family to ensure a sample of unrelated individuals (n = 1386).

In the CoLaus study, genome-wide SNP genotyping was performed using the Affymetrix 500 K SNP chip. Samples were excluded if they showed gender inconsistencies or had an efficiency <90%. Marker quality control resulted in exclusion of SNPs that were monomorphic (4052), had a call rate <95% (30 873), deviated (P < 10−3) from HWE (35 417) or had minor allele frequencies <0.01 (61 654), leaving a total number of 370 162 genotyped markers for analysis. Imputation of SNP genotypes was performed using the software IMPUTE v.0.5.0 based on the HapMap CEU II samples. Approximately 2.5 million markers were imputed. A total of 89 SNPs (34 genotyped and 55 imputed) within the CHRNA5-CHRNA3-CHRNB4 gene region were obtained. The SNP rs1051730 was imputed in the study sample with a posterior call rate of 0.97.

In the GOYA study, genome-wide SNP genotyping was performed using the Illumina 610 K Quad SNP chip. The rs1051730 SNP was genotyped on this platform. Individuals were excluded if they showed gender inconsistencies, if they had a genotyping success rate of <95%, if they had outlying heterozygosity (<0.30 or >0.35) or if they clustered with individuals of non-European ancestry on multi-dimensional scaling analysis. We also excluded one individual from each pair that appeared to be related (identity by descent > 0.2). The rs1051730 SNP had an overall call rate of 99.9% and the Hardy–Weinberg P-values were 0.21 and 0.44 in the controls and obese cases, respectively.

Statistical methods

Within-study analyses

Within each study, we verified that the association between smoking quantity and rs1051730 genotype was consistent in magnitude and direction with published data (data not shown, but the association has been previously published for the ALSPAC, CoLaus and EFSOCH women studies,). We then stratified by smoking status in each study (for our main analyses into never and ever strata, and for our second analyses into finer strata of never, former and current). To test for association between BMI and rs1051730 genotype within each stratum, we performed linear regression of log-transformed BMI against genotype (coded as 0, 1 or 2 T-alleles; additive genetic model). We repeated the analysis including age and sex (where appropriate) as covariables. We then analysed the association between BMI and genotype, adjusting for smoking quantity (cigarettes per day) where available, in the current and former smoker strata. In addition, we analysed the association between BMI and genotype, adjusting for measured cotinine levels (available in the BRHS, BWHHS and MIDSPAN studies only). In the MIDSPAN study, which includes related individuals, associations between BMI and SNP genotype were investigated using linear mixed effects regression models fitted using restricted maximum likelihood (REML). Family structure among the MIDSPAN offspring generation was accounted for by fitting random intercepts within sibships.

Meta-analysis

Meta-analysis statistics and plots were produced using the inverse-variance method (fixed effects), implemented in the ‘metan’ module developed for Stata (StataCorp, College Station, TX, USA). We pooled regression coefficients and standard errors from the linear regression analyses performed in the individual studies. We used the I statistic to estimate the percentage of total variation in study estimates that is because of between-study heterogeneity and derived 95% confidence intervals (95% CIs) for I2 using the user-written Stata command, ‘heterogi’. Conventionally, I values of 25, 50 and 75% represent low, moderate and high heterogeneity, respectively. In addition, we used Cochran’s Q-test to evaluate the statistical evidence for between-study heterogeneity, both within and between the strata defined by smoking status. The test of heterogeneity between strata served as a test of interaction between genotype and smoking status. As a sensitivity analysis, we repeated the meta-analysis excluding the ALSPAC and EFSOCH women studies, which analysed pre-pregnancy BMI, but which stratified by smoking status (never/former/current) using data collected during pregnancy.

Estimation of approximate overall effect sizes in kilogram per square metre

Since the outcome was natural log transformed, we obtained the percentage change in the average value of BMI per allele using 100 x [exp(beta)–1], where ‘beta’ is the effect size on the logBMI scale. We took the median study BMI within each stratum (never/former/current/ever) as the average value.

Results

The basic characteristics of study participants are presented in Table 1. The associations between BMI and the rs1051730 variant are presented (overall and by study) in Figure 1 and Tables 2 and 3. In the ever smokers, each additional T-allele, which is associated with greater smoking quantity, was associated with a 0.9% (95% CI: 0.5–1.2) lower BMI (P = 8 × 10−6). This equates to a difference of 0.23 kg/m2 (95% CI: 0.13–0.31), relative to the median study BMI for ever smokers (25.8 kg/m2). However, in the never smokers, we observed no evidence of association between BMI and the genotype [0.2% BMI change (−0.2 to 0.7)], which equates to 0.05 kg/m2 (95% CI: −0.05 to 0.18) per T-allele (median study BMI for never smokers = 25.5 kg/m2; P = 0.25). There was low heterogeneity within each of the two strata [I = 21% (95% CI: 0–62), P = 0.26 for never; I = 0% (95% CI: 0–65), P = 0.91 for ever smokers], but strong evidence of heterogeneity between the strata (P = 0.0001), indicating an interaction between genotype and smoking status in their association with BMI.

Table 1

Basic characteristics of study participants

Study	Sample group	Participants, na (% male)	Age, median (IQR)	BMI, median (IQR)
ALSPACb	Never smokers	3193 (0)	29 (26–32)	22.2 (20.5–24.4)
	Former smokers	1851 (0)	29 (25–32)	22.4 (20.7–24.8)
	Current smokers	1104 (0)	26 (24–30)	22.0 (20.3–24.7)
	Ever smokers	2955 (0)	28 (25–31)	22.3 (20.5–24.8)
	All	6148 (0)	28 (25–32)	22.2 (20.6–24.5)
BRHS	Never smokers	1124 (100)	67 (64–72)	26.3 (24.3–28.5)
	Former smokers	2243 (100)	69 (65–74)	26.9 (24.9–29.4)
	Current smokers	503 (100)	68 (64–72)	25.9 (23.4–28.1)
	Ever smokers	2746 (100)	69 (64–74)	26.7 (24.6–29.2)
	All	3870 (100)	68 (64–73)	26.6 (24.5–29.0)
BWHHS	Never smokers	2047 (0)	69 (64–73)	27.0 (24.0–30.0)
	Former smokers	1194 (0)	69 (64–74)	27.0 (25.0–31.0)
	Current smokers	393 (0)	67 (63–72)	26.0 (23.0–29.0)
	Ever smokers	1587 (0)	69 (64–73)	27.0 (24.0–30.0)
	All	3634 (0)	69 (64–73)	27.0 (24.0–30.0)
CoLaus	Never smokers	2193 (38.0)	53 (44–62)	25.3 (22.6–28.3)
	Former smokers	1801 (54.9)	56 (47–63)	25.8 (23.1–28.8)
	Current smokers	1432 (51.2)	50 (43–60)	24.7 (22.1–27.7)
	Ever smokers	3233 (53.3)	53 (45–62)	25.3 (22.6–28.3)
	All	5426 (47.1)	53 (44–62)	25.3 (22.6–28.3)
EFSOCH MEN	Never smokers	376 (100)	32 (30–36)	26.6 (24.6–28.7)
	Former smokers	181 (100)	33 (30–37)	26.5 (24.5–29.2)
	Current smokers	205 (100)	32 (27–25)	26.2 (23.2–29.2)
	Ever smokers	386 (100)	32 (29–36)	26.4 (24.0–29.2)
	All	762 (100)	32 (29–36)	26.5 (24.2–29.0)
EFSOCH_WOMENb	Never smokers	593 (0)	31 (29–34)	22.9 (21.1–25.3)
	Former smokers	118 (0)	29 (25–32)	23.4 (21.0–25.5)
	Current smokers	100 (0)	29 (24–32)	23.7 (20.9–27.7)
	Ever smokers	218 (0)	29 (25–32)	23.5 (20.9–26.6)
	All	811 (0)	31 (27–34)	23.0 (21.1–25.5)
GOYA MEN CONTROLS	Never smokers	174 (100)	44 (40–49)	25.4 (23.5–28.7)
	Former smokers	216 (100)	48 (42–54)	26.2 (24.2–28.4)
	Current smokers	390 (100)	47 (42–55)	25.6 (23.6–27.8)
	Ever smokers	606 (100)	47 (42–55)	25.8 (23.7–28.1)
	All	780 (100)	46 (41–53)	25.8 (23.6–28.2)
GOYA MEN OBESE	Never smokers	163 (100)	41 (37–45)	35.8 (32.2–39.9)
	Former smokers	148 (100)	43 (40–48)	35.2 (32.7–40.3)
	Current smokers	350 (100)	42 (38–47)	34.5 (31.6–38.2)
	Ever smokers	498 (100)	42 (39–47)	34.6 (31.8–38.6)
	All	661 (100)	42 (38–46)	34.9 (32.0–39.1)
MIDSPAN	Never smokers	996 (43.0)	45 (40–49)	25.5 (23.1–28.4)
	Former smokers	574 (49.7)	47 (42–50)	26.3 (24.0–29.2)
	Current smokers	536 (44.2)	46 (40–50)	24.6 (22.1–28.1)
	Ever smokers	1110 (47.0)	46 (41–50)	25.6 (23.0–28.8)
	All	2106 (45.1)	45 (41–49)	25.5 (23.0–28.6)

Ever smokers: former plus current. IQR: inter-quartile range.

aN included in main analysis.

bPre-pregnancy BMI was analysed in ALSPAC and EFSOCH_WOMEN.

Figure 1

Meta-analysis plots of the association between the rs1051730 variant and BMI, stratified by smoking status. (a) Never/ever smokers. There was strong evidence of heterogeneity between strata (P = 0.0001). In the ever smokers, the effect size equates to a 0.23 kg/m2 (95% CI: 0.13−0.31) lower BMI per T-allele. In the never smokers, there was no evidence of association [BMI difference per T-allele: 0.05 kg/m2 (95% CI: −0.05 to 0.18)]. (b) Never/former/current smokers. There was strong evidence of heterogeneity among the three strata (P = 0.0002). In the former and current smokers, there was a 0.16 kg/m2 (95% CI: 0.03–0.29) and 0.33 kg/m2 (95% CI: 0.18–0.48) lower BMI per T-allele, respectively. Overall, across all smoking status strata, each additional T-allele was associated with a 0.10 kg/m2 (95% CI: 0.03–0.18) lower BMI

Table 2

Associations between BMI and rs1051730 genotype in all study participants, stratified by smoking status (never/ever) and by study

			No. and BMI (95% CI) by rs1051730 genotype
Group	Study	Total no. of participants	CC		CT		TT		Per-T allele change in ln(BMI) (95% CI)a	P-valuea
Never smokers	ALSPAC	3193	1412	22.5 (22.3 to 22.7)	1403	22.8 (22.6 to 23.0)	378	22.8 (22.5 to 23.2)	0.010 (0.002 to 0.017)	0.01
	BRHS	1124	475	26.6 (26.2 to 26.9)	514	26.2 (26.0 to 26.5)	135	26.3 (25.7 to 27.0)	−0.006 (−0.018 to 0.005)	0.27
	BWHHS	2047	898	27.1 (26.8 to 27.4)	910	27.2 (26.9 to 27.5)	239	26.7 (26.1 to 27.3)	−0.004 (−0.015 to 0.007)	0.49
	CoLaus	2193	884	25.5 (25.2 to 25.7)	1016	25.6 (25.4 to 25.9)	293	25.7 (25.3 to 26.2)	0.005 (−0.004 to 0.015)	0.25
	EFSOCH_M	376	179	26.5 (26.0 to 27.0)	160	26.5 (26.0 to 27.0)	37	27.1 (26.0 to 28.4)	0.008 (−0.012 to 0.027)	0.43
	EFSOCH_W	593	264	23.4 (23.0 to 23.9)	272	23.7 (23.2 to 24.1)	57	23.4 (22.3 to 24.5)	0.004 (−0.017 to 0.024)	0.73
	GOYA_MC	174	73	25.7 (24.8 to 26.6)	83	26.2 (25.5 to 27.0)	18	25.5 (23.8 to 27.4)	0.005 (−0.027 to 0.038)	0.75
	GOYA_MO	163	74	36.2 (35.0 to 37.5)	68	36.0 (34.6 to 37.4)	21	35.2 (32.5 to 38.1)	−0.012 (−0.048 to 0.024)	0.50
	MIDSPAN	996	447	25.9 (25.5 to 26.3)	455	25.9 (25.5 to 26.3)	94	25.1 (24.4 to 25.9)	−0.008 (−0.024 to 0.007)	0.30
	Overall	10 859							0.002 (−0.002 to 0.007)	0.25
	Overallb	10 859							0.002 (−0.002 to 0.007)	0.25
Ever smokers	ALSPAC	2955	1323	22.9 (22.7 to 23.1)	1308	22.7 (22.5 to 22.9)	324	22.7 (22.3 to 23.1)	−0.006 (−0.015 to 0.002)	0.13
	BRHS	2746	1290	26.9 (26.7 to 29.1)	1162	26.7 (26.4 to 26.9)	294	26.7 (26.3 to 27.1)	−0.005 (−0.012 to 0.003)	0.23
	BWHHS	1587	700	27.4 (27.0 to 27.7)	723	27.1 (26.8 to 27.5)	164	26.6 (25.9 to 27.3)	−0.013 (−0.026 to 0.000)	0.05
	CoLaus	3233	1302	25.6 (25.4 to 25.8)	1509	25.3 (25.1 to 25.5)	422	25.2 (24.8 to 25.5)	−0.009 (−0.017 to −0.002)	0.01
	EFSOCH_M	386	182	26.4 (25.8 to 27.0)	162	26.4 (25.8 to 27.1)	42	26.4 (25.8 to 27.1)	−0.009 (−0.032 to 0.014)	0.43
	EFSOCH_W	218	103	24.2 (23.3 to 25.1)	91	24.2 (23.3 to 25.0)	24	22.5 (21.2 to 24.0)	−0.024 (−0.060 to 0.011)	0.18
	GOYA_MC	606	276	26.1 (25.8 to 26.5)	250	25.8 (25.4 to 26.2)	80	25.4 (24.6 to 26.1)	−0.015 (−0.030 to 0.000)	0.06
	GOYA_MO	498	220	35.2 (34.5 to 35.9)	219	34.7 (34.0 to 35.4)	59	34.5 (33.1 to 35.9)	−0.011 (−0.031 to 0.009)	0.26
	MIDSPAN	1110	510	26.0 (25.6 to 26.4)	479	25.6 (25.3 to 26.0)	121	25.2 (24.5 to 26.0)	−0.012 (−0.027 to 0.003)	0.12
	Overall	13 339							−0.009 (−0.012 to −0.005)	8 × 10−6
	Overallb	13 339							−0.008 (−0.012 to −0.004)	3 × 10−5

BMI values are geometric means and 95% CIs.

aFrom linear regression of ln(BMI) against genotype, assuming an additive genetic model.

bAdjusted for age and sex. Meta-analysis results for per-allele changes in logBMI (95% CI), excluding the pregnant women from the ALSPAC and EFSOCH_WOMEN studies were: −0.001 (−0.006 to 0.004) for never smokers and −0.009 (−0.013 to −0.005) for ever smokers.

EFSOCH_M, EFSOCH_MEN; EFSOCH_W, EFSOCH_WOMEN; GOYA_MC, GOYA_MEN_CONTROLS; GOYA_MO, GOYA_MEN_OBESE.

Table 3

Associations between BMI and rs1051730 genotype in the ever smokers, stratified by smoking status (former/current) and by study

			No. and BMI (95% CI) by rs1051730 genotype
Group	Study	Total no. of participants	CC		CT		TT		Per-T allele change in ln(BMI) (95% CI)a	P-valuea
Former smokers	ALSPAC	1851	858	23.0 (22.8 to 23.3)	806	22.8 (22.6 to 23.0)	187	22.6 (22.2 to 23.1)	−0.009 (−0.019 to 0.002)	0.10
	BRHS	2243	1067	27.1 (26.9 to 27.3)	934	27.0 (26.8 to 27.2)	242	26.8 (26.3 to 27.2)	−0.005 (−0.013 to 0.003)	0.26
	BWHHS	1194	532	27.7 (27.3 to 28.2)	542	27.6 (27.2 to 28.0)	120	26.9 (26.2 to 27.7)	−0.010 (−0.025 to 0.005)	0.18
	CoLaus	1801	738	26.0 (25.7 to 26.2)	838	25.9 (25.7 to 26.2)	225	25.8 (25.3 to 26.3)	−0.003 (−0.013 to 0.007)	0.51
	EFSOCH_M	181	88	26.5 (25.7 to 27.3)	73	27.5 (26.7 to 28.4)	20	25.2 (23.8 to 26.6)	−0.004 (−0.035 to 0.028)	0.82
	EFSOCH_W	118	61	23.9 (22.9 to 25.0)	48	23.9 (22.9 to 25.1)	9	21.9 (20.0 to 24.0)	−0.024 (−0.072 to 0.024)	0.33
	GOYA_MC	216	100	26.7 (24.8 to 27.4)	92	26.3 (25.6 to 27.0)	24	25.8 (24.3 to 27.5)	−0.016 (−0.043 to 0.011)	0.25
	GOYA_MO	148	63	35.5 (34.3 to 36.8)	69	35.8 (34.5 to 37.3)	16	35.2 (32.1 to 38.4)	0.000 (−0.038 to 0.038)	1.00
	MIDSPAN	574	251	26.7 (26.2 to 27.2)	260	26.3 (25.9 to 26.8)	63	26.9 (25.9 to 27.8)	−0.002 (−0.021 to 0.017)	0.86
	Overall	8326							−0.006 (−0.011 to −0.001)	0.01
	Overallb	8326							−0.006 (−0.010 to −0.001)	0.02
	Overallc	4169							−0.010 (−0.017 to −0.003)	0.008
Current smokers	ALSPAC	1104	465	22.7 (22.4 to 23.0)	502	22.5 (22.2 to 22.8)	137	22.8 (22.2 to 23.4)	−0.002 (−0.016 to 0.013)	0.82
	BRHS	503	223	25.9 (25.4 to 26.4)	228	25.2 (24.7 to 25.7)	52	26.4 (25.4 to 27.5)	−0.002 (−0.022 to 0.017)	0.82
	BWHHS	393	168	26.2 (25.6 to 26.9)	181	25.6 (25.0 to 26.3)	44	25.5 (24.1 to 27.0)	−0.017 (−0.043 to 0.008)	0.18
	CoLaus	1432	564	25.2 (24.9 to 25.5)	671	24.6 (24.3 to 24.8)	197	24.6 (24.1 to 25.1)	−0.015 (−0.026 to −0.004)	0.006
	EFSOCH_M	205	94	26.3 (25.5 to 27.1)	89	25.5 (24.7 to 26.5)	22	26.0 (24.2 to 28.0)	−0.014 (−0.047 to 0.020)	0.43
	EFSOCH_W	100	42	24.6 (23.0 to 26.3)	43	24.4 (23.2 to 25.7)	15	22.9 (21.0 to 24.9)	−0.029 (−0.084 to 0.025)	0.30
	GOYA_MC	390	176	25.8 (25.4 to 26.3)	158	25.5 (25.0 to 26.1)	56	25.2 (24.3 to 36.0)	−0.013 (−0.031 to 0.005)	0.15
	GOYA_MO	350	157	35.1 (34.2 to 35.9)	150	34.2 (33.4 to 35.0)	43	34.2 (32.8 to 35.8)	−0.016 (−0.039 to 0.007)	0.18
	MIDSPAN	536	259	25.3 (24.8 to 25.9)	219	24.8 (24.2 to 25.4)	58	23.5 (22.6 to 24.6)	−0.032 (−0.054 to −0.009)	0.007
	Overall	5013							−0.013 (−0.019 to −0.007)	6 × 10−5
	Overallb	5013							−0.012 (−0.018 to −0.006)	0.0001
	Overallc	4084							−0.014 (−0.021 to −0.007)	7 × 10−5
	Overalld	1364							−0.010 (−0.023 to 0.006)	0.13

BMI values are geometric means and 95% CIs.

aFrom linear regression of ln(BMI) against genotype, assuming an additive genetic model.

bAdjusted for age and sex.

cAdjusted for smoking quantity.

dAdjusted for cotinine levels.

Current smoking quantity was available in all nine study samples; former smoking quantity was available in ALSPAC, BWHHS, CoLaus and MIDSPAN only. Cotinine levels were available in BRHS, BWHHS and MIDSPAN current smokers only [for comparison, the pooled per allele change in logBMI (95% CI), adjusted for smoking quantity, in BRHS, BWHHS and MIDSPAN was −0.020 (−0.033 to −0.006)].

Meta-analysis results for per-allele changes in logBMI (95% CI), excluding the pregnant women from the ALSPAC and EFSOCH studies were: −0.005 (−0.010 to 0.000) for former smokers and −0.015 (−0.022 to −0.008) for current smokers.

EFSOCH_M, EFSOCH_MEN; EFSOCH_W, EFSOCH_WOMEN; GOYA_MC, GOYA_MEN_CONTROLS; GOYA_MO, GOYA_MEN_OBESE.

When dividing the ever-smoker group into current and former smokers, we observed evidence of association in both strata (Figure 1b and Table 3), but with a larger effect size in current smokers. In the former and current smokers, respectively, there was a 0.6% (95% CI: 0.1–1.1) and 1.3% (95% CI: 0.7–1.9) lower BMI per T-allele. These effect sizes equate, respectively, to differences of 0.16 kg/m2 (95% CI: 0.03–0.29) and 0.33 kg/m2 (95% CI: 0.18–0.48), relative to the median study BMIs in these groups (26.3 kg/m2 former and 25.6 kg/m2 current). There was no detectable heterogeneity within these strata [I = 0% (95% CI: 0–65), P = 0.97 for former; I = 0% (95% CI: 0–65), P = 0.55 for current smokers], but strong evidence of heterogeneity among the never, former and current smoker strata (P = 0.0002).

Overall, across all smoking status strata, each additional T-allele was associated with a 0.4% (95% CI: 0.1–0.7) lower BMI (P = 0.007; Figure 1), which equates to a difference of 0.10 kg/m2 (95% CI: 0.03–0.18) (median overall study BMI = 25.8 kg/m2).

The results were not materially altered on adjustment for age and sex (Tables 2 and 3). A sensitivity analysis excluding the ALSPAC and EFSOCH pregnant women produced very similar effect size estimates (Tables 2 and 3).

Adjustment for smoking quantity, where available, in the current and former smokers also did not substantially change the results (Table 3). Measured cotinine levels were available in the current smokers of the BRHS, BWHHS and MIDSPAN studies. Adjustment for cotinine levels resulted in attenuation of the association between genotype and BMI [1.0% (95% CI: –0.3 to 2.3)] lower per T-allele (P = 0.13), relative to the association adjusted for reported smoking quantity in BRHS, BWHHS and MIDSPAN only: 2.0% lower BMI (95% CI: 0.6–3.2, P = 0.005; Table 3).

Discussion

In a meta-analysis of 24 198 individuals from nine study samples, we have shown that there is an interaction between smoking status and genotype of the 15q25 variant, rs1051730, in relation to BMI. In never smokers, we observed no evidence of association between rs1051730 genotype and BMI. However, in ever smokers, there was strong evidence that each additional copy of the T-allele, which is associated with higher smoking quantity, was associated with a 0.23 kg/m2 (95% CI: 0.13–0.31) lower BMI (interaction P = 0.0001). The association in the ever smokers was consistent across studies (heterogeneity P = 0.91), despite variation in mean BMI because of age and ascertainment differences.

Our results support the hypothesis that exposure to cigarette smoking is causally associated with lower BMI. Genotype–phenotype associations are not biased by reverse causality, and genotypes are generally randomized to factors that usually confound epidemiological studies. We have shown previously that the rs1051730 variant, which is robustly associated with smoking quantity, is not associated with covariates of smoking behaviour including age, education level and occupational position. We can, therefore, be confident that the association we have observed between rs1051730 genotype and BMI in ever smokers, together with the null association in never smokers, reflects a causal relationship between smoking exposure and lower BMI. Our data add support to evidence from previous epidemiological, experimental and physiological studies.,,

Subdivision of the ever-smoker group showed that the effect size was smaller in former smokers [0.16 kg/m2 (95% CI: 0.03–0.29) lower BMI per T-allele] than in current smokers [0.33 kg/m2 (95% CI: 0.18–0.48) lower BMI per T-allele]. This suggests that the association with BMI weakens over time after cessation. It is consistent with the observation that cigarette smokers who attempt to quit experience a short-term rebound effect, whereby a marked initial weight gain following smoking cessation is a result of the removal of the lowered body weight set point induced by chronic nicotine use, and reduced sympathovagal ratio and resensitization of nicotinic receptors. Smoking cessation is associated with a corresponding average increase in BMI, and comparisons of BMI over time suggest that when cigarette smokers achieve long-term abstinence from tobacco they revert to a mean BMI roughly equivalent to that of never smokers. Weight gain on cessation of smoking is associated with increased risk of relapse into smoking. Taken together, these observations suggest that smoking cessation initiatives may be more successful if accompanied by support to maintain a healthy BMI.

We did not observe attenuation of the associations between genotype and BMI upon adjustment for smoking quantity in the former and current smokers. We would expect these associations to get weaker if, as we hypothesize, the genotype–BMI association is mediated by smoking quantity. However, since data on smoking quantity were self-reported, they were unlikely to have captured the exposure fully. Moreover, adjustment for cotinine levels in the available samples did result in attenuation, and our observation that there was no association between genotype and BMI in the never smokers is consistent with the associations observed being mediated by smoking. The observation that the effect of the rs1051730 variant on BMI is robust to adjustment for smoking quantity suggests that, even within heaviness of smoking strata, the rs1051730 variant exerts an influence on exposure, possibly via individual differences in smoking topography (e.g. depth of puff inhalation, number of puffs). This further supports a causal association between exposure and BMI, both between and within heaviness of smoking strata, and suggests that simple measures of heaviness of smoking based on reported quantity may mask important inter-individual variation in behaviour and subsequent exposure.

Although the association between rs1051730 genotype and smoking quantity has mostly been described in Europeans, it has also been observed in populations of African–American and Korean descent. Further work is needed to investigate the relationships between genotype, smoking and BMI in non-European populations.

We acknowledge some limitations to our study. First, in the ALSPAC and EFSOCH studies, pre-pregnancy BMI was analysed, whereas smoking data were collected during pregnancy. Therefore, the temporal distinction between former and current smokers may have been different from that in the other studies. However, a sensitivity analysis excluding these studies produced very similar effect size estimates of the associations within each smoking status stratum. Secondly, different methods and instruments were used for assessing weight and height, as well as smoking in the studies that were pooled here. However, we found little evidence for marked heterogeneity between studies within strata. Thirdly, our statistical evidence for association with BMI in the ever smokers (P = 8 × 10−6), and for the genotype × smoking status interaction (P = 0.0001), although strong, is modest in relation to levels now necessary for robust candidate gene association studies. However, the fact that the 15q25 variant is now incontrovertibly associated with smoking quantity greatly increases the prior odds of association.

To conclude, the 15q25 smoking quantity variant is associated with a lower BMI in former and current smokers, but not in individuals who have never smoked. This is a clear example of a gene × environment interaction because the association between genotype and BMI is dependent upon smoking status. Our observations support the hypothesis that smoking is causally associated with reduced BMI. Smoking cessation initiatives might be more successful if they include support to maintain a healthy BMI at the same time as quitting smoking.

Funding

The UK Medical Research Council, the Wellcome Trust and the University of Bristol (to ALSPAC); BRHS is a British Heart Foundation research group (current programme grant RG/08/013/25942); British Heart Foundation Senior Research Fellowship (award FS05/125, partial, to BRHS for DNA extraction); Department of Health (England) Policy Research Programme and the British Heart Foundation (to BWHHS); GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, Switzerland, and the Swiss National Science Foundation (33CSCO-122661) (to The CoLaus Study); Swiss National Science Foundation (#3200B0–105993, #3200B0-1180308, 33CSC0122661) and GlaxoSmithKline (Psychiatry Center of Excellence for Drug Discovery and Genetics Division, Drug Discovery—Verona, R&D) (to The PsyCoLaus Study); South West NHS Research and Development, Exeter NHS Research and Development, the Darlington Trust, and the Peninsula NIHR Clinical Research Facility at the University of Exeter (to EFSOCH); Wellcome Trust (grant WT084762) (to The Danish GOYA male study); Wellcome Trust and the NHS Research and Development Programme (to the offspring study in MIDSPAN); Sir Henry Wellcome Postdoctoral Fellowship (Wellcome Trust grant 085541/Z/08/Z) (to R.M.F.); UK Medical Research Council (G0600705) and the University of Bristol (to G.D.S. and D.A.L.).